Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
Holding REGN?
Track your performance easily
REGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$769.19 - $1,211.20
Previous Close$1,153.08
Volume348.69K
Average Volume (3M)463.61K
Market Cap
$127.09B
Enterprise Value$119.98B
Total Cash (Recent Filing)$9.81B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)30.5
Beta0.54
Next Earnings
Oct 31, 2024EPS Estimate
$11.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)37.76
Shares Outstanding110,234,529
10 Day Avg. Volume468,338
30 Day Avg. Volume463,605
Standard Deviation0.08
R-Squared0.00556
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4.51
Price to Sales (P/S)9.43
Price to Cash Flow (P/CF)89.80
P/FCF Ratio183.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.89
Enterprise Value/Gross Profit10.62
Enterprise Value/Ebitda23.49
Forecast
1Y Price Target
$1,185.39Price Target Upside3.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Regeneron News
Bulls Say, Bears Say
Bulls Say
Drug Approval And Revenue GrowthIf approved, Dupixent could contribute an additional $340M in revenue from the new indication, continuing to expand Regeneron's revenue overall and Dupixent's dominance in I&I diseases.
Financial PerformanceQ2 total revenue of $3.55B (+13% Q/Q; +12% Y/Y) was above consensus of $3.37B by 5%.
Pipeline And Future GrowthConsiderable focus on the pipeline, where upcoming catalysts are expected to support long-term growth.
Bears Say
Clinical TrialsA small Ph3 trial of Dupixent in uncontrolled and severe chronic pruritus of unknown origin did not achieve statistical significance in its primary itch responder endpoint.
Market CompetitionVabysmo's pre-filled syringe was approved and raises pressure on REGN's Eylea franchise.
Regulatory IssuesThe FDA issued a CRL for linvoseltamab for relapsed/refractory multiple myeloma.
---
Ownership Overview
2.87% Insiders
34.80% Mutual Funds
42.59% Other Institutional Investors
19.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $769.19 and its highest was $1211.20 in the past 12 months.
What is Regeneron’s market cap?
Currently, no data Available
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Aug 01, 2024. The company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $10.618 by $0.942.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is $11.84.
How many shares outstanding does Regeneron have?
Regeneron has 108,417,380 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $11.56 in its last earnings report, beating expectations of $10.618. Following the earnings report the stock price went up 1.293%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,185.39 (3.37% Upside)
$1,185.39 (3.37% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 109.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.03%
12-Months-Change
Fundamentals
Return on Equity
16.55%
Trailing 12-Months
Asset Growth
17.71%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
REGN Company Deck
---
REGN Earnings Call
Q2 2024
0:00 / 0:00
---
REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
REGN Stock 12 Month Forecast
Average Price Target
$1,185.39
▲(3.37% Upside)
Technical Analysis
Best Analysts Covering REGN
1 Year
1 Year Success Rate
24/25 ratings generated profit
1 Year Average Return
+25.10%
assigned a buy rating 13 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 96.00% of your transactions generating a profit, with an average return of +25.10% per trade.
---